Pharma Journalist -

Kyttaro announces that it has entered into an agreement for the worldwide exclusive license of an anti-angiopoietin-like (ANGPTL) 3/8 monoclonal antibody program developed by Eli Lilly…
Read More...

Glenmark Pharmaceuticals Limited, an innovation-driven, global pharmaceutical company, announced that its subsidiary Glenmark Specialty S.A. (Glenmark) received approval from the Indian…
Read More...

Opus Genetics, a patient-focused gene therapy company developing treatments for inherited retinal diseases, announced a strategic manufacturing services agreement with National…
Read More...

BIOASIS TECHNOLOGIES INC. a biopharmaceutical company developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”),…
Read More...

Ardelyx, Inc. a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs,…
Read More...

Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced the first participants have been dosed in the Phase 1/2 study of the Company's…
Read More...

Harbour BioMed announced a global out-license agreement with AstraZeneca for CLDN18.2xCD3 bispecific antibody (HBM7022), a novel bispecific antibody generated from HBM's HCAb Based…
Read More...

Jazz Pharmaceuticals plc and Werewolf Therapeutics, Inc. announced that the companies have entered into a licensing agreement under which Jazz has acquired exclusive global development…
Read More...

Novavax, Inc. a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII),…
Read More...

SMi Group reports: Exclusive speaker interview released with Takeda Pharmaceutical Company Ltd ahead of the Highly Potent API Conference Now in its 6th year, the Highly Potent Active…
Read More...